Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Low-Dose immune booster tame ALS inflammation?

NCT ID NCT03039673

Completed Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether low-dose interleukin-2 (IL-2) can help control nerve inflammation in people newly diagnosed with ALS. Over 18 months, 304 participants received either IL-2 or a placebo, alongside standard riluzole treatment. The goal was to see if boosting regulatory T cells could slow the disease and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
low-dose interleukin-2 (IL-2)
What this could lead to
If it works, this could point toward a treatment that slows ALS progression and extends survival by calming nerve inflammation.
What could go wrong
This is a mid-stage trial with 304 participants, so results may not be conclusive. ALS is complex, and boosting immune cells might not slow the disease in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

  • APHM - Hôpital de la Timone

    Marseille, 13385, France

  • APHP - Groupe Hospitalier Pitié-Salpetrière

    Paris, 75651, France

  • CENTRE HOSPITALIER DE SAINT BRIEUC - Hôpital Yves Le Foll

    Saint-Brieuc, 22027, France

  • CHRU de Lille - Hôpital Roger Salengro

    Lille, 59037, France

  • CHRU de Montpellier - Hôpital Gui de Chauliac

    Montpellier, 34295, France

  • CHRU de Tours - Hôpital Bretonneau

    Tours, 37044, France

  • CHU de Limoges - Hôpital Dupuytren

    Limoges, 87042, France

  • CHU de Nice - Hôpital Pasteur

    Nice, 06002, France

  • CHU de Strasbourg - Hôpital de Hautepierre

    Strasbourg, 67098, France

  • Centre for Neuromuscular Diseases - National Hospital of Neurology

    London, WC1N 3BG, United Kingdom

  • HCL - Hôpital Neurologique P. Wertheimer

    Lyon, 69677, France

  • Institute of Neurological Sciences, Queen Elizabeth University Hospital

    Glasgow, G514TF, United Kingdom

  • King's MND Care and Research Centre

    London, SE5 8AF, United Kingdom

  • North-East London and Essex MND Regional Care Centre

    London, E1 4NS, United Kingdom

  • Salford Royal NHS Foundation Trust, Neurology Dept

    Manchester, M6 8HD, United Kingdom

  • Sheffield Care and Research Centre

    Sheffield, S10 2JF, United Kingdom

  • Trafford Centre for Biomedical Research

    Brighton, BN1 9RY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.